Wayne Solley, M.D.
NPI 1528042447 · Ophthalmology Physician · Arlington, TX
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1528042447
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- K7398 (TX)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
8,997 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Imaging of Retina92134 | 3,371 | $41 |
| Established Patient Complete Exam of Visual System92014 | 2,710 | $128 |
| Injection of Drug Into Eye67028 | 2,320 | $133 |
| New Patient Office Or Other Outpatient Visit With Moderate Level of Medical Decision Making, If Using Time, 45 Minutes Or More99204 | 245 | $172 |
| Established Patient Problem Focused Exam of Visual System92012 | 72 | $92 |
| Compounded Drug, Not Otherwise ClassifiedJ7999 | 58 | $94 |
| Removal of Membrane of Retina With Removal of Internal Limiting Membrane of Retina |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 12 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Prednisolone Acetate | 262 | 190 |
| Moxifloxacin Hclbrand: Moxifloxacin | 203 | 159 |
| Dorzolamide Hcl/Timolol Maleatbrand: Dorzolamide-Timolol | 89 | 43 |
| Tramadol Hcl | 79 | 72 |
| Neomycin/Polymyxin B/Dexamethabrand: Neomycin-Polymyxin-Dexameth | 61 | 45 |
| Tobramycin/Dexamethasonebrand: Tobramycin-Dexamethasone | 59 | 48 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$12,721 across 36 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-12-05
- Last updated
- 2011-12-01
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.